1.
Anaerobic storage of red blood cells in a novel additive solution improves in vivo recovery
Dumont LJ, Yoshida T, Herschel L, Dumont D, Waters S, Baker S, AuBuchon JP
Transfusion. 2008;48((S2):):38A.. Abstract No. S101-030M.
2.
A randomized, controlled, 2-period crossover study of recovery and lifespan of radiolabeled autologous 35-day-old red blood cells prepared with a modified s-303 treatment for pathogen inactivation
Cancelas JA, Dumont L, Herschel L, Roger J, Rugg N, Arndt P, Propst M, Laurence L, Sundin D, AuBuchon J
Vox Sanguinis. 2008;95((Suppl 1):):8. Abstract No. 2A-SO1-03.
3.
In vivo and in vitro evaluation of the ONE-STEP LEUKOSEPâ„¢ Filtration System for Red Blood Cells
Rugg N, Cancelas JA, Pratt PG, Gormas JF, Joines A, AuBuchon JP, Herschel L, Rogers J, Zia M, Kandler R
Transfusion. 2006;46((9s):):75A.. Abstract No. SP116.
4.
In vitro evaluation of the ONE-STEP LEUKOSEPâ„¢ Filtration System for Red Blood Cells
Rugg N, Cancelas JA, Pratt PG, Gormas JF, Joines AD, AuBuchon JP, Herschel L, Roger J, Zia M, Spearman M
Transfusion. 2005;45((s3):):70A.. Abstract No. SP131.
5.
Transfusion to blood group A and O patients of group B RBCs that have been enzymatically converted to group O
Kruskall MS, AuBuchon JP, Anthony KY, Herschel L, Pickard C, Biehl R, Horowitz M, Brambilla DJ, Popovsky MA
Transfusion. 2000;40((11):):1290-8.
Abstract
BACKGROUND The transfusion of ABO-incompatible RBCs is the leading cause of fatal transfusion reactions. Group O RBCs, lacking terminal immunodominant A and B sugars to which humans are immunized, are safe for transfusion to persons of any ABO blood group. With the use of a recombinant alpha-galactosidase to remove terminal galactose from group B RBCs, the safety and efficacy of enzyme-converted group-B-to-group-O (ECO) RBC components were studied in transfusion-dependent patients. STUDY DESIGN AND METHODS Twenty-four patients (blood groups A and O) were randomly assigned to receive transfusion(s) of either ECO or control group O RBCs. If a second transfusion was given, the other blood component was administered. RESULTS Twenty-one patients were given ECO RBCs; 18 also underwent control transfusions. One patient received only a small aliquot for RBC survival studies, instead of a full-unit transfusion, because his serum was incompatible with ECO RBCs. No adverse events occurred. Both ECO and control transfusions resulted in appropriate Hb increments and comparable (51)Cr-labeled RBC survival studies. One patient developed a transient, weak-positive DAT, without hemolysis. Two weeks after transfusion, 5 of 19 evaluable ECO RBC recipients had increases in anti-B titers. CONCLUSION ECO RBCs were comparable to group O cells for safety and efficacy in this study. The clinical significance of the increase in anti-B and of occasional serologic incompatibilities with ECO RBCs is unclear. If strategies can be developed to remove A epitopes, enzymatic conversion could be used to create a universal (group O) donor blood supply.
6.
Transfusion of enzymatically converted (group B to group O) red cells to patients: a phase II trial
Kruskall MS, AuBuchon JP, Anthony KY, Herschel L, Pickard C, Biehl R,, et al.,
Transfusion. 1998;38((10S):):86S.. Abstract No. S324.
7.
Recovery and long-term survival of enzyme-converted group O red blood cells after transfusion into patients
AuBuchon JP, Pickard C, Herschel L
Transfusion. 1998;38((10S):):3S.. Abstract No. P9.